Nigeria Counterfeit Bevacizumab and Atezolizumab Alert
Analysis based on 12 articles · First reported Mar 19, 2026 · Last updated Mar 20, 2026
The circulation of counterfeit Bevacizumab and Atezolizumab in Nigeria creates significant market uncertainty for pharmaceutical companies, particularly Roche, and erodes consumer trust in the drug supply chain. This event will likely lead to increased scrutiny and regulatory measures within the Nigerian pharmaceutical market, potentially impacting sales and distribution channels.
The Nigeria===National Agency for Food and Drug Administration and Control has issued a public alert concerning the widespread circulation of counterfeit cancer medicines, Bevacizumab and Atezolizumab, across Nigeria. This warning follows multiple complaints received by Roche Nigeria from healthcare professionals regarding suspected fake products. Investigations revealed discrepancies in packaging, batch numbers, and serialisation, indicating the presence of falsified drugs. These counterfeit medicines, often sold at suspiciously low prices, pose severe health risks, including treatment failure, disease progression, and death, as they may contain incorrect or no active ingredients. The Nigeria===National Agency for Food and Drug Administration and Control has directed intensified surveillance and removal of these products from circulation, urging vigilance among all stakeholders in the pharmaceutical supply chain.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard